PMID 40094000
The GLP-1 component suppresses appetite and improves insulin secretion
Different brands and formulations have different storage instructions
Still, the studys scale, duration and granular clinical data provide meaningful evidence to inform riskbenefit discussions. Balancing risks and benefits Importantly, the analysis assessed risk associated with initiation of semaglutide rather than cumulative dose or treatment duration. Whether risk varies by dosing intensity or length of exposure remains an open question
Bollu, PhD 5 Krithika Rajagopalan, PhD 4 Author Affiliations | Correspondence | Abstract | Citation | Keywords | PDF Author Affiliations Pulmonary Research Institute of Southeast Michigan, Farmington Hills Clinical Research Institute of Southern Oregon, PC, Medford University of North Carolina School of Medicine, Chapel Hill Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts Abilytic, Inc., Shrewsbury, Massachusetts Address correspondence to: Gary T